340 related articles for article (PubMed ID: 35383532)
1. Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.
Wang Y; Cai F; Li G; Tao Y
Bioengineered; 2022 Apr; 13(4):9184-9196. PubMed ID: 35383532
[TBL] [Abstract][Full Text] [Related]
2. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
5. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.
Cui J; Shang A; Wang W; Chen W
Life Sci; 2020 Nov; 260():118339. PubMed ID: 32841660
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus.
Wang D; Jiang L; Feng B; He N; Zhang Y; Ye H
J Diabetes Investig; 2020 Jan; 11(1):39-51. PubMed ID: 31199578
[TBL] [Abstract][Full Text] [Related]
7. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
8. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
9. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
10.
Wang Y; Zheng X; Li L; Wang H; Chen K; Xu M; Wu Y; Huang X; Zhang M; Ye X; Xu T; Chen R; Zhu Y
Food Nutr Res; 2020; 64():. PubMed ID: 33061882
[TBL] [Abstract][Full Text] [Related]
11. Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
Wang Y; Sun H; Zhang J; Xia Z; Chen W
Biosci Biotechnol Biochem; 2020 Dec; 84(12):2533-2544. PubMed ID: 32892714
[TBL] [Abstract][Full Text] [Related]
12. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
Spielman LJ; Gibson DL; Klegeris A
Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
[TBL] [Abstract][Full Text] [Related]
13. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
14. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
15. HMGCS2 silencing attenuates high glucose-induced in vitro diabetic cardiomyopathy by increasing cell viability, and inhibiting apoptosis, inflammation, and oxidative stress.
Chen D; Ruan X; Liu Y; He Y
Bioengineered; 2022 May; 13(5):11417-11429. PubMed ID: 35506308
[TBL] [Abstract][Full Text] [Related]
16. SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress.
Huang Y; Zhang J; Xu D; Peng Y; Jin Y; Zhang L
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760202
[TBL] [Abstract][Full Text] [Related]
17. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
18. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
[TBL] [Abstract][Full Text] [Related]
19. Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress.
Gu X; Shi Y; Chen X; Sun Z; Luo W; Hu X; Jin G; You S; Qian Y; Wu W; Liang G; Wu G; Chen Z; Chen X
Phytomedicine; 2020 Nov; 78():153319. PubMed ID: 32950951
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Al-Damry NT; Attia HA; Al-Rasheed NM; Al-Rasheed NM; Mohamad RA; Al-Amin MA; Dizmiri N; Atteya M
Biomed Pharmacother; 2018 Nov; 107():347-358. PubMed ID: 30099338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
